Comparison. Research use only.
Epithalon vs NAD+
Two compounds that appear together in longevity research discussion but sit at opposite ends of the evidence spectrum. Epithalon is a synthetic tetrapeptide studied for telomerase induction, and its literature is small and largely from a single research group. NAD+ is a fundamental redox cofactor, and it is also consumed as a substrate by sirtuins, PARPs and CD38. The body of work behind it is very large and independent.
Epithalon
Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, whose sequence was derived from the amino acid composition of Epithalamin, a bovine pineal gland extract. Telling the two apart is essential when reading this literature. Epithalamin is a complex peptide extract, whereas Epithalon is a single defined synthetic tetrapeptide, and the two have largely separate evidence bases. The most-cited proposed mechanism is telomere-related. Telomeres are the protective caps at the ends of chromosomes that shorten as cells divide. Adding Epithalon to telomerase-negative human fetal fibroblast cultures was reported to induce expression of the telomerase catalytic subunit, enzymatic telomerase activity, and telomere elongation. A follow-up reported that treated fibroblasts underwent approximately ten additional passages beyond the control replicative limit. A 2025 independent study reported dose-dependent telomere elongation in normal epithelial and fibroblast cells via hTERT and telomerase upregulation, and telomere extension in breast cancer cell lines via the Alternative Lengthening of Telomeres pathway, with the ALT contribution largely specific to cancer cells. Note that this paper carries a published correction. A second proposed mechanism involves direct interaction with nucleic acids. Short regulatory peptides have been reported to bind the DNA double helix and modulate gene transcription, though the structural and biophysical characterization of that interaction remains limited. In rodent models, Epithalon has been reported to reduce chromosome aberration frequency in bone marrow cells and to downregulate HER-2/neu transcript expression in mammary tumors of transgenic mice. Importantly, the frequently asserted claim that Epithalon restores melatonin secretion is not supported by direct measurement. An independent perifusion study found that Ala-Glu-Asp-Gly had no significant effect on melatonin secretion by pineal glands from either young or old rats, and did not modify stimulated melatonin release. The overall mechanistic picture remains poorly resolved.
NAD+
NAD+ is a redox cofactor, a molecule cells use to shuttle electrons. It cycles between an oxidized and a reduced state, accepting a hydride at the C4 position of its nicotinamide ring. In that role it is the principal electron carrier for glycolysis, the tricarboxylic acid cycle and fatty acid beta-oxidation, delivering reducing equivalents to complex I of the mitochondrial electron transport chain. Separately from that redox cycling, NAD+ is consumed as a substrate by three enzyme families that cut the glycosidic bond and release nicotinamide: the sirtuin NAD+-dependent protein deacylases, the poly(ADP-ribose) polymerases, and the NAD+ glycohydrolases CD38 and CD157, together with SARM1 in axonal degeneration. Because these enzymes destroy NAD+ rather than recycle it, cells must continuously make more. Mammalian cells regenerate NAD+ mainly through the salvage pathway. In that pathway nicotinamide phosphoribosyltransferase (the rate-limiting step) converts nicotinamide to nicotinamide mononucleotide, and adenylyltransferases then convert that to NAD+ in distinct subcellular compartments. Two additional routes contribute: de novo synthesis from tryptophan via the kynurenine pathway, and the Preiss-Handler pathway from nicotinic acid. The core preclinical hypothesis under investigation is that tissue NAD+ availability declines with age and metabolic stress, partly through increased consumption and reduced salvage activity, and that raising NAD+ with precursors restores sirtuin and mitochondrial function. How far that translates to clinical benefit in humans remains unresolved, and the best-controlled trials to date have produced null results on functional endpoints.
Other research peptide comparisons
Both compounds in stock at Veridian. 99%+ HPLC purity, same-day US shipping.
Browse all research peptides →